Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
42.28
+0.38 (0.91%)
At close: Dec 31, 2025, 4:00 PM EST
41.65
-0.63 (-1.49%)
After-hours: Dec 31, 2025, 7:11 PM EST
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.79M in the quarter ending September 30, 2025, a decrease of -51.13%. This brings the company's revenue in the last twelve months to $62.60M, down -32.79% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$62.60M
Revenue Growth
-32.79%
P/S Ratio
10.32
Revenue / Employee
$1,026,230
Employees
61
Market Cap
860.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
| Dec 31, 2018 | 1.19B | 885.61M | 287.81% |
| Dec 31, 2017 | 307.71M | 142.28M | 86.00% |
| Dec 31, 2016 | 165.44M | -65.35M | -28.32% |
| Dec 31, 2015 | 230.78M | 30.08M | 14.99% |
| Dec 31, 2014 | 200.71M | 51.79M | 34.77% |
| Dec 31, 2013 | 148.92M | 67.73M | 83.42% |
| Dec 31, 2012 | 81.19M | 9.71M | 13.59% |
| Dec 31, 2011 | 71.48M | -87.56M | -55.06% |
| Dec 31, 2010 | 159.04M | 87.11M | 121.10% |
| Dec 31, 2009 | 71.93M | -18.25M | -20.24% |
| Dec 31, 2008 | 90.19M | -182.84M | -66.97% |
| Dec 31, 2007 | 273.03M | 55.31M | 25.40% |
| Dec 31, 2006 | 217.72M | 91.44M | 72.41% |
| Dec 31, 2005 | 126.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NKTR News
- 15 days ago - Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg - Seeking Alpha
- 16 days ago - Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript - Seeking Alpha
- 16 days ago - Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion - Benzinga
- 17 days ago - Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 - PRNewsWire
- 27 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets - Seeking Alpha
- 7 weeks ago - Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout - Seeking Alpha
- 7 weeks ago - New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - PRNewsWire